Sun Pharma gets a domestic boost in Q2, but it’s too early to rejoice
Revenues from the US region were flat in the second quarter of FY20 compared with last year
Sun Pharma’s domestic business saw a year-on-year growth of 35%, the highest in six years
Sun Pharmaceutical Industries Ltd’s second quarter figures have outrun estimates, showing that the firm is getting back on the recovery path. The stock surged immediately after the results and ended Thursday about 3% higher.
Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!Let’s get started